---
title: "\"Performance\" WINFULL GP's interim loss narrows to 35.485 million yuan"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277350900.md"
description: "WINFULL GP announced its interim results for the six months ending December 2025, with revenue recorded at HKD 54.44 million, an increase of 126.8% year-on-year. The loss narrowed from HKD 53.09 million in the same period last year to HKD 35.485 million, with a loss per share of 6.26 cents. No dividend was declared"
datetime: "2026-03-01T10:53:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277350900.md)
  - [en](https://longbridge.com/en/news/277350900.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277350900.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277350900.md) | [繁體中文](https://longbridge.com/zh-HK/news/277350900.md)


# "Performance" WINFULL GP's interim loss narrows to 35.485 million yuan

WINFULL GP (00183.HK) announced its interim results for the six months ending December 2025, with revenue recorded at HKD 54.44 million, an increase of 126.8% year-on-year. The loss narrowed from HKD 53.09 million in the same period last year to HKD 35.485 million, with a loss per share of 6.26 cents. No dividend was declared

### 相关股票

- [WINFULL GP (00183.HK)](https://longbridge.com/zh-CN/quote/00183.HK.md)

## 相关资讯与研究

- [LG Chem CEO says it is difficult to secure additional Russian naphtha](https://longbridge.com/zh-CN/news/281110331.md)
- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-CN/news/281035263.md)
- [Osl Group FY adjusted non-IFRS income HK$534.1 million](https://longbridge.com/zh-CN/news/281223382.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [Huatai Securities Keeps Their Buy Rating on C&D International Investment Group Ltd. (1908)](https://longbridge.com/zh-CN/news/280868130.md)